BioStock: Elicera receives funding for clinical trials with ELC-301

Gene therapy company Elicera Therapeutics has been awarded 2.5 million Euros in funding from the European Innovation Council (EIC) Accelerator Programme. The grant is great news for the company, which now has sufficient funds to conduct Elicera's planned clinical phase I/II study evaluating its CAR T-cell therapy ELC-301 in the treatment of B-cell lymphoma.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/06/elicera-erhaller-finansiering-for-kliniska-studier-med-elc-301/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/